scholarly journals Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy

2017 ◽  
Vol Volume 11 ◽  
pp. 1543-1553 ◽  
Author(s):  
Norman B Gaylis ◽  
Joanne Sagliani ◽  
Shawn Black ◽  
Kezhen L Tang ◽  
Raphael DeHoratius ◽  
...  
Author(s):  
Nikunj Patel ◽  
Joshua Maher ◽  
Xandra Lie ◽  
Chad Gwaltney ◽  
Afsaneh Barzi ◽  
...  

Abstract Purpose This study aimed to elucidate the patient experience of hepatocellular carcinoma (HCC) to guide patient-centered outcome measurement in drug development. Methods Patients with HCC participated in qualitative interviews to elicit disease-related signs/symptoms and impacts, using discussion guides developed from literature searches and discussions with oncologists. Interview participants rated the disturbance of their experiences (0–10 scale). A conceptual model was developed and mapped against patient-reported outcome (PRO) instruments identified from database reviews. Results Interviews were conducted with 25 individuals with HCC (68% were men; median age: 63 years; 12% Barcelona clinic liver cancer (BCLC) stage A; 32% stage B; and 56% stage C) in the USA. Fifty-one HCC-related concepts were identified from the interviews and were grouped into eight sign/symptom categories (eating behavior/weight changes; extremities [arms, legs]; fatigue and strength; gastrointestinal; pain; sensory; skin; other) and four impact categories (emotional; physical; cognitive function; other) for the conceptual model. The most prevalent and disturbing experiences across the disease stages were fatigue/lack of energy and emotional impacts such as frustration, fear, and depression. Abdominal pain and skin-related issues were particularly common and disturbing in individuals with HCC stage C. The EORTC QLQ-C30 and HCC18 were identified as commonly used PRO instruments in HCC studies and captured the relevant signs/symptoms associated with the patient experience. Conclusion Patients with HCC reported a range of signs/symptoms and impacts that negatively affect daily functioning and quality of life. Including PRO measures in HCC clinical trials can provide meaningful patient perspectives during drug development.


2010 ◽  
Vol 62 (11) ◽  
pp. 1639-1645 ◽  
Author(s):  
Karen Herlyn ◽  
Bernhard Hellmich ◽  
Philip Seo ◽  
Peter A. Merkel

BMJ ◽  
2019 ◽  
pp. k5267 ◽  
Author(s):  
Melanie Calvert ◽  
Derek Kyte ◽  
Gary Price ◽  
Jose M Valderas ◽  
Niels Henrik Hjollund

Antibiotics ◽  
2018 ◽  
Vol 7 (2) ◽  
pp. 43 ◽  
Author(s):  
Jakhongir Alidjanov ◽  
Kurt Naber ◽  
Ulugbek Abdufattaev ◽  
Adrian Pilatz ◽  
Florian Wagenlehner

Cancer ◽  
2018 ◽  
Vol 124 (14) ◽  
pp. 3066-3067
Author(s):  
Fabio Efficace ◽  
Francesco Cottone ◽  
Francesco Sparano ◽  
Francesco Lo-Coco

2020 ◽  
Vol 18 (2) ◽  
pp. 288-292
Author(s):  
Binit Vaidya ◽  
Manisha Bhochhibhoya ◽  
Rakshya Joshi ◽  
Bhoj raj Adhikari ◽  
Shweta Nakarmi

Background: Undifferentiated inflammatory arthritis is a group of inflammatory joint diseases that do not fulfil the classification criteria for any other rheumatic or connective tissue disorders. This study aims to describe the clinical, demographic and serological features of undifferentiated inflammatory arthritis cases presenting at a tertiary level rheumatology centre from Nepal.Methods: A descriptive cross-sectional study conducted at National Centre for Rheumatic Diseases, Kathmandu, Nepal which represents a midterm analysis of the undifferentiated inflammatory arthritis registry maintained at the centre. Patients more than 18 years of age, who consented for the study having least one swollen or tender joint were enrolled. Ethical approval was obtained from Nepal Health Research Council.Results: A total of 1120 patients were enrolled in the study out of which 941 (84%) were females. The mean age at diagnosis was 46.0±12.8 years and most of them were in overweight range (mean BMI: 27.0±5.8) with 818 (73%) patients having BMI more than 24.0. Patients mostly had low disease activity at presentation (DAS 28 score of 2.5±0.8). Other markers of inflammation and patient reported outcome measures (health assessment questionnaire, patient global assessment and visual analogue scale) were also in the moderate range. Seropositivity for anti-citrullinated peptides and anti-nuclear antibodies was seen in 5 (0.45%) and 43 (3.8%) patients respectively. Majority of patients were non-smokers (77%). Inflammatory arthritis on musculoskeletal ultrasonography was seen in 638 (57%).Conclusions: Undifferentiated inflammatory arthritis was more common in overweight females. Serological markers and smoking status are not common features in these patients. Keywords: Early arthritis; Nepal; undifferentiated arthritis.


Sign in / Sign up

Export Citation Format

Share Document